CO2017004290A2 - Composiciones y métodos para el silenciamiento de la expresión génica del virus de la hepatitis b - Google Patents
Composiciones y métodos para el silenciamiento de la expresión génica del virus de la hepatitis bInfo
- Publication number
- CO2017004290A2 CO2017004290A2 CONC2017/0004290A CO2017004290A CO2017004290A2 CO 2017004290 A2 CO2017004290 A2 CO 2017004290A2 CO 2017004290 A CO2017004290 A CO 2017004290A CO 2017004290 A2 CO2017004290 A2 CO 2017004290A2
- Authority
- CO
- Colombia
- Prior art keywords
- virus
- methods
- gene expression
- hepatitis
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462059056P | 2014-10-02 | 2014-10-02 | |
| US201562120149P | 2015-02-24 | 2015-02-24 | |
| PCT/US2015/053569 WO2016054421A1 (en) | 2014-10-02 | 2015-10-01 | Compositions and methods for silencing hepatitis b virus gene expression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2017004290A2 true CO2017004290A2 (es) | 2017-09-20 |
Family
ID=54325078
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2017/0004290A CO2017004290A2 (es) | 2014-10-02 | 2017-04-27 | Composiciones y métodos para el silenciamiento de la expresión génica del virus de la hepatitis b |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US10415037B2 (https=) |
| EP (1) | EP3201338B1 (https=) |
| JP (1) | JP2017536092A (https=) |
| KR (1) | KR20170075742A (https=) |
| CN (1) | CN107208095B (https=) |
| AU (1) | AU2015328012A1 (https=) |
| BR (1) | BR112017006679A2 (https=) |
| CA (1) | CA2963271A1 (https=) |
| CL (1) | CL2017000780A1 (https=) |
| CO (1) | CO2017004290A2 (https=) |
| CR (1) | CR20170174A (https=) |
| IL (1) | IL251450A0 (https=) |
| PH (1) | PH12017500614A1 (https=) |
| RU (1) | RU2017114964A (https=) |
| SG (1) | SG11201702662UA (https=) |
| TW (2) | TW201900876A (https=) |
| WO (1) | WO2016054421A1 (https=) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009238175C1 (en) * | 2008-04-15 | 2023-11-30 | Arbutus Biopharma Corporation | Novel lipid formulations for nucleic acid delivery |
| ES2613498T3 (es) | 2009-07-01 | 2017-05-24 | Protiva Biotherapeutics Inc. | Nuevas formulaciones de lípidos para el suministro de agentes terapéuticos a tumores sólidos |
| HUE042177T2 (hu) | 2009-12-01 | 2019-06-28 | Translate Bio Inc | Szteroidszármazék mRNS szállítására humán genetikai betegségekben |
| WO2012000104A1 (en) | 2010-06-30 | 2012-01-05 | Protiva Biotherapeutics, Inc. | Non-liposomal systems for nucleic acid delivery |
| WO2012075040A2 (en) | 2010-11-30 | 2012-06-07 | Shire Human Genetic Therapies, Inc. | mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES |
| PL3586861T3 (pl) | 2011-06-08 | 2022-05-23 | Translate Bio, Inc. | Kompozycje nanocząstek lipidowych i sposoby dostarczania mrna |
| US10245229B2 (en) | 2012-06-08 | 2019-04-02 | Translate Bio, Inc. | Pulmonary delivery of mRNA to non-lung target cells |
| EP3536787A1 (en) | 2012-06-08 | 2019-09-11 | Translate Bio, Inc. | Nuclease resistant polynucleotides and uses thereof |
| DK2970456T3 (da) | 2013-03-14 | 2021-07-05 | Translate Bio Inc | Fremgangsmåder og sammensætninger til levering af mrna-kodede antistoffer |
| PL3467108T3 (pl) | 2013-03-14 | 2024-09-30 | Translate Bio, Inc. | Sposoby oczyszczania informacyjnego rna |
| KR20210122917A (ko) | 2013-03-14 | 2021-10-12 | 샤이어 휴먼 지네틱 테라피즈 인크. | Cftr mrna 조성물 및 관련 방법 및 사용 |
| US10130649B2 (en) | 2013-03-15 | 2018-11-20 | Translate Bio, Inc. | Synergistic enhancement of the delivery of nucleic acids via blended formulations |
| MX2016005238A (es) | 2013-10-22 | 2016-08-12 | Shire Human Genetic Therapies | Formulaciones de lipidos para la administracion de acido ribonucleico mensajero. |
| EA034103B1 (ru) | 2013-10-22 | 2019-12-27 | Транслейт Био, Инк. | СПОСОБ ЛЕЧЕНИЯ ФЕНИЛКЕТОНУРИИ С ПРИМЕНЕНИЕМ мРНК |
| AU2014340149B2 (en) | 2013-10-22 | 2020-12-24 | Shire Human Genetic Therapies, Inc. | CNS delivery of mRNA and uses thereof |
| ES2707966T3 (es) | 2013-10-22 | 2019-04-08 | Translate Bio Inc | Terapia de ARNm para la deficiencia en síntesis de argininosuccinato |
| PT3134506T (pt) | 2014-04-25 | 2019-10-31 | Translate Bio Inc | Métodos de purificação de rna mensageiro |
| JP6557722B2 (ja) | 2014-05-30 | 2019-08-07 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | 核酸の送達のための生分解性脂質 |
| EP3160959B1 (en) | 2014-06-24 | 2023-08-30 | Translate Bio, Inc. | Stereochemically enriched compositions for delivery of nucleic acids |
| BR112016030852A2 (pt) | 2014-07-02 | 2018-01-16 | Shire Human Genetic Therapies | encapsulação de rna mensageiro |
| WO2016090262A1 (en) | 2014-12-05 | 2016-06-09 | Shire Human Genetic Therapies, Inc. | Messenger rna therapy for treatment of articular disease |
| US10172924B2 (en) | 2015-03-19 | 2019-01-08 | Translate Bio, Inc. | MRNA therapy for pompe disease |
| JP6924744B2 (ja) | 2015-07-17 | 2021-08-25 | アークトゥラス・セラピューティクス・インコーポレイテッドＡｒｃｔｕｒｕｓ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | Ｂ型肝炎ウイルスに対する組成物および薬剤ならびにその使用 |
| US20170137821A1 (en) | 2015-07-17 | 2017-05-18 | Arcturus Therapeutics, Inc. | Molecules and agents for treating hepatitis b virus |
| CN108350455A (zh) * | 2015-07-29 | 2018-07-31 | 阿布特斯生物制药公司 | 用于使b型肝炎病毒基因表达沉默的组合物和方法 |
| CN114686548A (zh) | 2015-10-14 | 2022-07-01 | 川斯勒佰尔公司 | 用于增强生产的rna相关酶的修饰 |
| WO2017177169A1 (en) | 2016-04-08 | 2017-10-12 | Rana Therapeutics, Inc. | Multimeric coding nucleic acid and uses thereof |
| CA3027312A1 (en) | 2016-06-13 | 2017-12-21 | Translate Bio, Inc. | Messenger rna therapy for the treatment of ornithine transcarbamylase deficiency |
| TWI794190B (zh) * | 2016-11-07 | 2023-03-01 | 加拿大商愛彼特生物製藥公司 | 含有取代的吡啶酮之三環化合物及其使用方法 |
| AU2017379901B2 (en) | 2016-12-21 | 2024-02-15 | Arbutus Biopharma Corporation | Methods for ameliorating infusion reactions |
| EA201991747A1 (ru) | 2017-02-27 | 2020-06-04 | Транслейт Био, Инк. | НОВАЯ КОДОН-ОПТИМИЗИРОВАННАЯ мРНК CFTR |
| MX2019013752A (es) | 2017-05-16 | 2020-07-20 | Translate Bio Inc | Tratamiento de la fibrosis quística mediante el suministro de arnm que codifica cftr optimizado en codones. |
| AR112166A1 (es) * | 2017-06-16 | 2019-09-25 | Arbutus Biopharma Corp | Composiciones terapéuticas y métodos para el tratamiento de hepatitis b |
| CN107291266B (zh) * | 2017-06-21 | 2018-08-31 | 腾讯科技（深圳）有限公司 | 图像显示的方法和装置 |
| WO2019051257A2 (en) * | 2017-09-11 | 2019-03-14 | Arbutus Biopharma Corporation | METHODS OF TREATING HEPATITIS B TYPE INFECTIONS |
| UA126931C2 (uk) | 2017-10-16 | 2023-02-22 | Ф. Хоффманн-Ля Рош Аг | МОЛЕКУЛИ НУКЛЕЇНОВИХ КИСЛОТ ДЛЯ ЗМЕНШЕННЯ РІВНЯ мРНК PAPD5 І PAPD7 ДЛЯ ЛІКУВАННЯ ІНФЕКЦІЙНОГО ГЕПАТИТУ B |
| EP3727428A1 (en) | 2017-12-20 | 2020-10-28 | Translate Bio, Inc. | Improved composition and methods for treatment of ornithine transcarbamylase deficiency |
| US11702427B2 (en) | 2018-03-12 | 2023-07-18 | Arbutus Biopharma Corporation | Substituted 2-pyridone tricyclic compounds, analogues thereof, and methods using same |
| MA52661A (fr) * | 2018-04-05 | 2021-02-17 | Centre Leon Berard | Utilisation d'inhibiteurs de fubp1 dans le traitement d'une infection par le virus de l'hépatite b |
| AU2019252441A1 (en) | 2018-04-12 | 2020-10-22 | Arbutus Biopharma Corporation | Methods for preparing substituted pyridinone-containing tricyclic compounds |
| CA3108544A1 (en) | 2018-08-24 | 2020-02-27 | Translate Bio, Inc. | Methods for purification of messenger rna |
| US20210395751A1 (en) * | 2018-10-31 | 2021-12-23 | The University Of Sydney | Compositions and methods for treating viral infections |
| KR20210105889A (ko) | 2018-11-09 | 2021-08-27 | 아뷰터스 바이오파마 코포레이션 | 지질 나노입자 제제 |
| US20220001029A1 (en) * | 2018-11-09 | 2022-01-06 | Arbutus Biopharma Corporation | Lipid nanoparticle formulations |
| MX2021005969A (es) | 2018-11-21 | 2021-09-14 | Translate Bio Inc | Tratamiento de la fibrosis quística mediante el suministro de arnm que codifica cftr nebulizado. |
| EP3902910A1 (en) | 2018-12-24 | 2021-11-03 | Selexis S.A. | Characterization and inactivation of endogenous retroviruses in chinese hamster ovary cells |
| CA3164931A1 (en) | 2019-12-24 | 2021-07-01 | Selexis Sa | Targeted integration in mammalian sequences enhancing gene expression |
| RU2733361C1 (ru) * | 2020-07-14 | 2020-10-01 | Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России (ФГБУ "ГНЦ Институт иммунологии" ФМБА России) | Средство для ингибирования репликации вируса SARS-CoV-2, опосредованного РНК-интерференцией |
| RU2746362C9 (ru) * | 2021-03-11 | 2021-04-26 | Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России (ФГБУ "ГНЦ Институт иммунологии" ФМБА России) | Комбинированное лекарственное средство, обладающее противовирусным эффектом в отношении нового коронавируса SARS-CoV-2 |
| CN118900641A (zh) * | 2022-01-17 | 2024-11-05 | 埃斯普投资有限公司 | 具有改善的储存稳定性的可生物降解的微胶囊、其制备方法及其使用方法 |
Family Cites Families (108)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3993754A (en) | 1974-10-09 | 1976-11-23 | The United States Of America As Represented By The United States Energy Research And Development Administration | Liposome-encapsulated actinomycin for cancer chemotherapy |
| US4086257A (en) | 1976-10-12 | 1978-04-25 | Sears Barry D | Phosphatidyl quaternary ammonium compounds |
| CH624011A5 (https=) | 1977-08-05 | 1981-07-15 | Battelle Memorial Institute | |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4522803A (en) | 1983-02-04 | 1985-06-11 | The Liposome Company, Inc. | Stable plurilamellar vesicles, their preparation and use |
| US4588578A (en) | 1983-08-08 | 1986-05-13 | The Liposome Company, Inc. | Lipid vesicles prepared in a monophase |
| US5208036A (en) | 1985-01-07 | 1993-05-04 | Syntex (U.S.A.) Inc. | N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
| US5725871A (en) | 1989-08-18 | 1998-03-10 | Danbiosyst Uk Limited | Drug delivery compositions comprising lysophosphoglycerolipid |
| US5286634A (en) | 1989-09-28 | 1994-02-15 | Stadler Joan K | Synergistic method for host cell transformation |
| US5707644A (en) | 1989-11-04 | 1998-01-13 | Danbiosyst Uk Limited | Small particle compositions for intranasal drug delivery |
| US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| US5283185A (en) | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
| US5756353A (en) | 1991-12-17 | 1998-05-26 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol-and liposome-based delivery |
| ES2105262T3 (es) | 1992-05-18 | 1997-10-16 | Minnesota Mining & Mfg | Dispositivo de suministro de farmaco a traves de las mucosas. |
| US5792451A (en) | 1994-03-02 | 1998-08-11 | Emisphere Technologies, Inc. | Oral drug delivery compositions and methods |
| US5426039A (en) | 1993-09-08 | 1995-06-20 | Bio-Rad Laboratories, Inc. | Direct molecular cloning of primer extended DNA containing an alkane diol |
| FR2715847B1 (fr) | 1994-02-08 | 1996-04-12 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucléiques, préparation et utilisations. |
| FR2722506B1 (fr) | 1994-07-13 | 1996-08-14 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucleiques, preparation et utilisations |
| US5908635A (en) | 1994-08-05 | 1999-06-01 | The United States Of America As Represented By The Department Of Health And Human Services | Method for the liposomal delivery of nucleic acids |
| US5753613A (en) | 1994-09-30 | 1998-05-19 | Inex Pharmaceuticals Corporation | Compositions for the introduction of polyanionic materials into cells |
| ATE219660T1 (de) | 1994-09-30 | 2002-07-15 | Inex Pharmaceuticals Corp | Mittel zum einbringen polyanionischer materialien in zellen |
| US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
| US5580579A (en) | 1995-02-15 | 1996-12-03 | Nano Systems L.L.C. | Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers |
| IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
| US5756122A (en) | 1995-06-07 | 1998-05-26 | Georgetown University | Liposomally encapsulated nucleic acids having high entrapment efficiencies, method of manufacturer and use thereof for transfection of targeted cells |
| US7422902B1 (en) | 1995-06-07 | 2008-09-09 | The University Of British Columbia | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| US5981501A (en) | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
| ATE285477T1 (de) | 1995-06-07 | 2005-01-15 | Inex Pharmaceutical Corp | Herstellung von lipid-nukleinsäure partikeln duch ein hydrophobische lipid-nukleinsäuree komplexe zwischenprodukt und zur verwendung in der gentransfer |
| US5705385A (en) | 1995-06-07 | 1998-01-06 | Inex Pharmaceuticals Corporation | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| IL115199A (en) | 1995-09-07 | 2005-05-17 | Opperbas Holding Bv | Composition comprising a polynucleic acid molecule in a liposome and method using said composition |
| US6620805B1 (en) | 1996-03-14 | 2003-09-16 | Yale University | Delivery of nucleic acids by porphyrins |
| US6756054B1 (en) | 1996-05-24 | 2004-06-29 | Ic-Vec Limited | Polycationic sterol derivatives as transfection agents |
| JP4320054B2 (ja) | 1996-08-13 | 2009-08-26 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | ポリヌクレオチド送達のための組成物および方法 |
| US20030229040A1 (en) | 1997-03-21 | 2003-12-11 | Georgetown University | Cationic liposomal delivery system and therapeutic use thereof |
| US6126965A (en) | 1997-03-21 | 2000-10-03 | Georgetown University School Of Medicine | Liposomes containing oligonucleotides |
| CA2289702C (en) | 1997-05-14 | 2008-02-19 | Inex Pharmaceuticals Corp. | High efficiency encapsulation of charged therapeutic agents in lipid vesicles |
| DE69834038D1 (de) | 1997-07-01 | 2006-05-18 | Isis Pharmaceutical Inc | Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhre |
| US20030073640A1 (en) | 1997-07-23 | 2003-04-17 | Ribozyme Pharmaceuticals, Inc. | Novel compositions for the delivery of negatively charged molecules |
| US6110745A (en) | 1997-07-24 | 2000-08-29 | Inex Pharmaceuticals Corp. | Preparation of lipid-nucleic acid particles using a solvent extraction and direct hydration method |
| CA2301166A1 (en) | 1997-07-24 | 1999-02-04 | Yuan-Peng Zhang | Liposomal compositions for the delivery of nucleic acid catalysts |
| US6320017B1 (en) | 1997-12-23 | 2001-11-20 | Inex Pharmaceuticals Corp. | Polyamide oligomers |
| US7091192B1 (en) | 1998-07-01 | 2006-08-15 | California Institute Of Technology | Linear cyclodextrin copolymers |
| US6509323B1 (en) | 1998-07-01 | 2003-01-21 | California Institute Of Technology | Linear cyclodextrin copolymers |
| WO2000003683A2 (en) | 1998-07-20 | 2000-01-27 | Inex Pharmaceuticals Corporation | Liposomal encapsulated nucleic acid-complexes |
| ATE511543T1 (de) | 1999-02-22 | 2011-06-15 | Univ Georgetown | Immunoliposome mit einem targeting- antikörperfragment zur systemischen genverabreichung |
| WO2000062813A2 (en) | 1999-04-20 | 2000-10-26 | The University Of British Columbia | Cationic peg-lipids and methods of use |
| US6852334B1 (en) | 1999-04-20 | 2005-02-08 | The University Of British Columbia | Cationic peg-lipids and methods of use |
| US7112337B2 (en) | 1999-04-23 | 2006-09-26 | Alza Corporation | Liposome composition for delivery of nucleic acid |
| US7098032B2 (en) | 2001-01-02 | 2006-08-29 | Mirus Bio Corporation | Compositions and methods for drug delivery using pH sensitive molecules |
| US6200599B1 (en) | 1999-10-07 | 2001-03-13 | The Regents Of The University Of California | Ortho ester lipids |
| US20050037086A1 (en) | 1999-11-19 | 2005-02-17 | Zycos Inc., A Delaware Corporation | Continuous-flow method for preparing microparticles |
| JP2003528131A (ja) | 2000-03-29 | 2003-09-24 | アラダイム コーポレーション | カチオン性リポソーム |
| US7189705B2 (en) | 2000-04-20 | 2007-03-13 | The University Of British Columbia | Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers |
| US20040142475A1 (en) | 2000-06-02 | 2004-07-22 | Barman Shikha P. | Delivery systems for bioactive agents |
| US20030072794A1 (en) | 2000-06-09 | 2003-04-17 | Teni Boulikas | Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes |
| US7427394B2 (en) | 2000-10-10 | 2008-09-23 | Massachusetts Institute Of Technology | Biodegradable poly(β-amino esters) and uses thereof |
| US7053150B2 (en) | 2000-12-18 | 2006-05-30 | Nektar Therapeutics Al, Corporation | Segmented polymers and their conjugates |
| TW593427B (en) | 2000-12-18 | 2004-06-21 | Nektar Therapeutics Al Corp | Synthesis of high molecular weight non-peptidic polymer derivatives |
| TWI321054B (en) | 2000-12-19 | 2010-03-01 | California Inst Of Techn | Compositions containing inclusion complexes |
| US7108863B2 (en) | 2001-03-26 | 2006-09-19 | Alza Corporation | Liposome composition for improved intracellular delivery of a therapeutic agent |
| WO2002076427A2 (en) | 2001-03-26 | 2002-10-03 | Thomas Jefferson University | Ph sensitive liposomal drug delivery |
| US20030026831A1 (en) | 2001-04-20 | 2003-02-06 | Aparna Lakkaraju | Anionic liposomes for delivery of bioactive agents |
| US20030077829A1 (en) | 2001-04-30 | 2003-04-24 | Protiva Biotherapeutics Inc.. | Lipid-based formulations |
| JP2004535388A (ja) | 2001-04-30 | 2004-11-25 | ターゲティッド ジェネティクス コーポレイション | 脂質含有薬物送達複合体およびそれらの生成方法 |
| DE10127526A1 (de) | 2001-05-31 | 2002-12-12 | Novosom Ag | Verfahren zur Herstellung und Auflösung von Nano- und Mikrokapseln |
| US7063860B2 (en) | 2001-08-13 | 2006-06-20 | University Of Pittsburgh | Application of lipid vehicles and use for drug delivery |
| US7101995B2 (en) | 2001-08-27 | 2006-09-05 | Mirus Bio Corporation | Compositions and processes using siRNA, amphipathic compounds and polycations |
| DE10152145A1 (de) | 2001-10-19 | 2003-05-22 | Novosom Ag | Stabilisierung von Liposomen und Emulsionen |
| EP1575976A4 (en) | 2001-11-02 | 2006-08-23 | Insert Therapeutics Inc | METHODS AND COMPOSITIONS FOR THE THERAPEUTIC USE OF RNA INTERFERENCE |
| DE10157046A1 (de) | 2001-11-18 | 2003-06-12 | Novosom Ag | Nano- und Mikrokapseln umfassend Reaktivpolymere |
| AU2002359892A1 (en) | 2001-12-31 | 2003-07-24 | Elan Pharmaceuticals, Inc. | Efficient nucleic acid encapsulation into medium sized liposomes |
| CA2472462A1 (en) | 2002-01-09 | 2003-07-24 | Elan Pharmaceuticals, Inc. | Efficient nucleic acid encapsulation into medium sized liposomes |
| EP1480657A4 (en) | 2002-02-01 | 2006-07-05 | Intradigm Corp | POLYMERS FOR ADMINISTERING PEPTIDES AND SMALL MOLECULES IN VIVO / I |
| DE10207177A1 (de) | 2002-02-19 | 2003-09-04 | Novosom Ag | Fakultativ kationische Lipide |
| US20050222064A1 (en) | 2002-02-20 | 2005-10-06 | Sirna Therapeutics, Inc. | Polycationic compositions for cellular delivery of polynucleotides |
| EP1476492A1 (en) | 2002-02-22 | 2004-11-17 | Insert Therapeutics Inc. | Carbohydrate-modified polymers, compositions and uses related thereto |
| US7037520B2 (en) | 2002-03-22 | 2006-05-02 | Baylor College Of Medicine | Reversible masking of liposomal complexes for targeted delivery |
| WO2003083443A2 (en) | 2002-03-29 | 2003-10-09 | University Of Florida | Lipid mediated screening of drug candidates for identification of active compounds |
| ES2328031T3 (es) | 2002-05-24 | 2009-11-06 | F. Hoffmann-La Roche Ag | Composiciones para distribuir acidos nucleicos a celulas. |
| CA2488856A1 (en) | 2002-06-20 | 2003-12-31 | Cytos Biotechnology Ag | Packaged virus-like particles for use as adjuvants: method of preparation and use |
| US7901708B2 (en) | 2002-06-28 | 2011-03-08 | Protiva Biotherapeutics, Inc. | Liposomal apparatus and manufacturing methods |
| US7682626B2 (en) | 2003-02-07 | 2010-03-23 | Roche Madison Inc. | Polyvinylethers for delivery of polynucleotides to mammalian cells |
| ES2559828T3 (es) | 2003-07-16 | 2016-02-16 | Protiva Biotherapeutics Inc. | ARN de interferencia encapsulado en lípidos |
| NZ592917A (en) | 2003-09-15 | 2012-12-21 | Protiva Biotherapeutics Inc | Stable polyethyleneglycol (PEG) dialkyloxypropyl (DAA) lipid conjugates |
| US7745651B2 (en) | 2004-06-07 | 2010-06-29 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods of use |
| US7799565B2 (en) | 2004-06-07 | 2010-09-21 | Protiva Biotherapeutics, Inc. | Lipid encapsulated interfering RNA |
| SG124419A1 (en) | 2005-02-03 | 2006-08-30 | Agency Science Tech & Res | Polycations capable of forming complexes with nucleic acids |
| US7404969B2 (en) | 2005-02-14 | 2008-07-29 | Sirna Therapeutics, Inc. | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules |
| JP5042863B2 (ja) | 2005-02-14 | 2012-10-03 | サーナ・セラピューティクス・インコーポレイテッド | 生物学的に活性な分子をデリバリーするための脂質ナノ粒子系組成物および方法 |
| US9005654B2 (en) | 2005-07-27 | 2015-04-14 | Protiva Biotherapeutics, Inc. | Systems and methods for manufacturing liposomes |
| EP3192788A1 (en) | 2006-10-03 | 2017-07-19 | Arbutus Biopharma Corporation | Lipid containing formulations |
| BRPI0811170B8 (pt) | 2007-05-22 | 2021-05-25 | Arcturus Therapeutics Inc | oligonucleotídeos de rna e complexos de rna substituídos por hidroximetila |
| WO2009086558A1 (en) | 2008-01-02 | 2009-07-09 | Tekmira Pharmaceuticals Corporation | Improved compositions and methods for the delivery of nucleic acids |
| AU2009238175C1 (en) | 2008-04-15 | 2023-11-30 | Arbutus Biopharma Corporation | Novel lipid formulations for nucleic acid delivery |
| CN101603042B (zh) | 2008-06-13 | 2013-05-01 | 厦门大学 | 可用于乙型肝炎病毒感染治疗的rna干扰靶点 |
| JP5642673B2 (ja) | 2008-07-10 | 2014-12-17 | セリナ・セラピユーテイツクス・インコーポレーテツド | 不活性末端基を有するポリオキサゾリン類、保護された開始基から調製されるポリオキサゾリン類及び関連化合物 |
| SG171879A1 (en) | 2008-12-03 | 2011-07-28 | Marina Biotech Inc | Usirna complexes |
| US20110071208A1 (en) | 2009-06-05 | 2011-03-24 | Protiva Biotherapeutics, Inc. | Lipid encapsulated dicer-substrate interfering rna |
| US8569256B2 (en) | 2009-07-01 | 2013-10-29 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods for the delivery of therapeutic agents |
| ES2613498T3 (es) | 2009-07-01 | 2017-05-24 | Protiva Biotherapeutics Inc. | Nuevas formulaciones de lípidos para el suministro de agentes terapéuticos a tumores sólidos |
| US20130190383A1 (en) | 2010-04-26 | 2013-07-25 | Marina Biotech, Inc. | Nucleic acid compounds with conformationally restricted monomers and uses thereof |
| WO2012024170A2 (en) * | 2010-08-17 | 2012-02-23 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| HRP20181564T1 (hr) | 2011-06-30 | 2018-11-30 | Arrowhead Pharmaceuticals, Inc. | Pripravci i postupci za inhibiciju ekspresije gena virusa hepatitisa b |
| WO2013159109A1 (en) * | 2012-04-20 | 2013-10-24 | Isis Pharmaceuticals, Inc. | Modulation of hepatitis b virus (hbv) expression |
-
2015
- 2015-10-01 BR BR112017006679A patent/BR112017006679A2/pt not_active Application Discontinuation
- 2015-10-01 US US15/515,952 patent/US10415037B2/en active Active
- 2015-10-01 JP JP2017517791A patent/JP2017536092A/ja active Pending
- 2015-10-01 KR KR1020177011725A patent/KR20170075742A/ko not_active Withdrawn
- 2015-10-01 SG SG11201702662UA patent/SG11201702662UA/en unknown
- 2015-10-01 AU AU2015328012A patent/AU2015328012A1/en not_active Abandoned
- 2015-10-01 WO PCT/US2015/053569 patent/WO2016054421A1/en not_active Ceased
- 2015-10-01 RU RU2017114964A patent/RU2017114964A/ru not_active Application Discontinuation
- 2015-10-01 EP EP15781007.8A patent/EP3201338B1/en active Active
- 2015-10-01 CA CA2963271A patent/CA2963271A1/en not_active Abandoned
- 2015-10-01 CR CR20170174A patent/CR20170174A/es unknown
- 2015-10-01 CN CN201580062374.9A patent/CN107208095B/zh active Active
- 2015-10-02 TW TW107110295A patent/TW201900876A/zh unknown
- 2015-10-02 TW TW104132625A patent/TW201623614A/zh unknown
-
2017
- 2017-03-29 IL IL251450A patent/IL251450A0/en unknown
- 2017-03-31 CL CL2017000780A patent/CL2017000780A1/es unknown
- 2017-04-03 PH PH12017500614A patent/PH12017500614A1/en unknown
- 2017-04-27 CO CONC2017/0004290A patent/CO2017004290A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201702662UA (en) | 2017-04-27 |
| TW201900876A (zh) | 2019-01-01 |
| BR112017006679A2 (pt) | 2017-12-26 |
| EP3201338B1 (en) | 2021-11-03 |
| AU2015328012A2 (en) | 2018-06-14 |
| PH12017500614A1 (en) | 2017-09-25 |
| CA2963271A1 (en) | 2016-04-07 |
| US20180016583A1 (en) | 2018-01-18 |
| JP2017536092A (ja) | 2017-12-07 |
| WO2016054421A1 (en) | 2016-04-07 |
| CR20170174A (es) | 2017-11-07 |
| EP3201338A1 (en) | 2017-08-09 |
| AU2015328012A1 (en) | 2017-05-11 |
| US10415037B2 (en) | 2019-09-17 |
| IL251450A0 (en) | 2017-05-29 |
| RU2017114964A (ru) | 2018-11-07 |
| CL2017000780A1 (es) | 2017-11-03 |
| CN107208095A (zh) | 2017-09-26 |
| RU2017114964A3 (https=) | 2018-11-07 |
| TW201623614A (zh) | 2016-07-01 |
| CN107208095B (zh) | 2021-11-16 |
| KR20170075742A (ko) | 2017-07-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2017004290A2 (es) | Composiciones y métodos para el silenciamiento de la expresión génica del virus de la hepatitis b | |
| HK1248278A1 (zh) | 用於使乙型肝炎病毒基因表达沉默的组合物及方法 | |
| MX2023013140A (es) | Vacunas contra el virus de la hepatitis b. | |
| GT201500020A (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| BR112017012859A2 (pt) | fosforamidatos para o tratamento do vírus da hepatite b | |
| WO2016183366A3 (en) | Compositions and methods for silencing expression of hepatitis d virus rna | |
| MX421406B (es) | Composiciones de acido ribonucleico de interferencia (arni) contra el virus de la hepatitis b (hbv) y metodos de uso de estas | |
| MX2021007679A (es) | Anticuerpos humanos para hemaglutinina de influenza. | |
| CR20170424A (es) | Tratamiento combinado con un agonista de tlr7 y un inhibidor del ensamblaje de la cápsula del vhb | |
| EA201790597A1 (ru) | Способы лечения вирусных инфекций filoviridae | |
| MX381042B (es) | Uso de un complejo quelato y un anàlogo de neucleòsido o neucleòtido para tratar infecciones de virus de la hepatitis b y hepatitis d. | |
| CL2018001946A1 (es) | Virus atenuados de bronquitis infecciosa. | |
| MX387275B (es) | Neoepítopos virales y sus usos | |
| BR112017023425A2 (pt) | combinações terapêuticas de terapias antivirais e anti-inflamatórias | |
| DOP2017000115A (es) | Composiciones farmacéuticas de acción prolongada para la hepatitis c | |
| DOP2017000116A (es) | Composiciones de acción prolongada de combinación y procedimientos para hepatitis c | |
| AR105532A1 (es) | Composiciones y métodos para silenciar la expresión génica del virus de la hepatitis b | |
| AR102614A1 (es) | COMPOSICIONES DE ARNi DEL VIRUS DE HEPATITIS D (HDV) Y MÉTODOS PARA SU USO | |
| AR105611A1 (es) | TERAPIA ARNi PARA INFECCIÓN POR VIRUS DE HEPATITIS B | |
| CR20150060A (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b. |